RSCM
Rock Springs Capital Management Portfolio holdings
AUM
$1.6B
This Quarter Return
-6.58%
1 Year Return
+25.98%
3 Year Return
+194.74%
5 Year Return
+336.76%
10 Year Return
+2,199.29%
AUM
$3.73B
AUM Growth
+$3.73B
(-11%)
Cap. Flow
-$74.6M
Cap. Flow
% of AUM
-2%
Top 10 Holdings %
Top 10 Hldgs %
36%
Holding
129
New
6
Increased
41
Reduced
24
Closed
9
Top Buys
| 1 |
Boston Scientific
BSX
|
$47.1M |
| 2 |
Penumbra
PEN
|
$33.3M |
| 3 |
BPMC
Blueprint Medicines
BPMC
|
$25M |
| 4 |
Immunovant
IMVT
|
$24.7M |
| 5 |
Amgen
AMGN
|
$18.3M |
Top Sells
| 1 |
argenx
ARGX
|
$44.7M |
| 2 |
Spyre Therapeutics
SYRE
|
$40.1M |
| 3 |
Insulet
PODD
|
$28.5M |
| 4 |
CONMED
CNMD
|
$27.9M |
| 5 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
$27.7M |
Sector Composition
| 1 | Healthcare | 97.08% |
| 2 | Consumer Staples | 1.17% |
| 3 | Industrials | 0.83% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
OLK
51
DELISTED
Olink Holding AB (publ) American Depositary Shares
OLK
| $24.7M | 0.66% | 1,676,500 +22,500 | +1% | +$332K |
|
52
Azenta
AZTA
$1.4B
| $24M | 0.64% | 477,500 +7,600 | +2% | +$381K |
|
53
BioMarin Pharmaceuticals
BMRN
$11.2B
| $23.4M | 0.63% | 264,500 | – | – |
|
|
NVRO
54
DELISTED
NEVRO CORP.
NVRO
| $23.3M | 0.62% | 1,211,600 +200 | +0% | +$3.84K |
|
55
Immatics
IMTX
$619M
| $21.7M | 0.58% | 1,875,466 -660,678 | -26% | -$7.65M |
|
56
Kymera Therapeutics
KYMR
$2.95B
| $20.9M | 0.56% | 1,504,351 +16,800 | +1% | +$234K |
|
57
Warby Parker
WRBY
$3.2B
| $20.7M | 0.56% | 1,575,000 +250,000 | +19% | +$3.29M |
|
58
Revolution Medicines
RVMD
$7.1B
| $20.1M | 0.54% | 725,152 +22,440 | +3% | +$621K |
|
59
Merus
MRUS
$4.98B
| $19.8M | 0.53% | 838,428 +359,897 | +75% | +$8.49M |
|
|
60
Amgen
AMGN
$155B
| $18.3M | 0.49% | +68,000 | New | +$18.3M |
|
61
BioCryst Pharmaceuticals
BCRX
$1.74B
| $18.1M | 0.48% | 2,551,226 +54,033 | +2% | +$383K |
|
62
Disc Medicine
IRON
$2.07B
| $17.1M | 0.46% | 363,468 | – | – |
|
63
Travere Therapeutics
TVTX
$1.56B
| $16.2M | 0.43% | 1,807,742 +280,022 | +18% | +$2.5M |
|
|
INZY
64
DELISTED
Inozyme Pharma
INZY
| $15.5M | 0.41% | 3,681,174 +253,090 | +7% | +$1.06M |
|
65
Celldex Therapeutics
CLDX
$1.47B
| $13.8M | 0.37% | 500,101 +78,486 | +19% | +$2.16M |
|
66
Amicus Therapeutics
FOLD
$2.34B
| $12.9M | 0.35% | 1,063,806 | – | – |
|
67
Collegium Pharmaceutical
COLL
$1.22B
| $12.6M | 0.34% | 562,000 -88,000 | -14% | -$1.97M |
|
|
IMGN
68
DELISTED
Immunogen Inc
IMGN
| $12.1M | 0.32% | 759,365 +646,745 | +574% | +$10.3M |
|
69
Acumen Pharmaceuticals
ABOS
$82.4M
| $11.7M | 0.31% | +2,812,579 | New | +$11.7M |
|
70
Mineralys Therapeutics
MLYS
$1.03B
| $11.1M | 0.3% | 1,167,492 | – | – |
|
71
Compass Therapeutics
CMPX
$483M
| $10.9M | 0.29% | 5,513,788 | – | – |
|
72
Krystal Biotech
KRYS
$4.27B
| $10.5M | 0.28% | 90,560 +55,659 | +159% | +$6.46M |
|
|
MREO
73
Mereo BioPharma
MREO
$272M
| $9.9M | 0.27% | 7,676,481 +634,090 | +9% | +$818K |
|
|
EDAP
74
EDAP TMS
EDAP
$84.5M
| $9.55M | 0.26% | 1,360,000 +173,700 | +15% | +$1.22M |
|
75
Inspire Medical Systems
INSP
$2.77B
| $8.83M | 0.24% | +44,500 | New | +$8.83M |
|